136
Views
1
CrossRef citations to date
0
Altmetric
Original Research

Assessing the Usefulness of the Prevexair Smartphone Application in the Follow-Up High-Risk Patients with COPD

ORCID Icon, , ORCID Icon, ORCID Icon, , , , ORCID Icon & ORCID Icon show all
Pages 53-65 | Published online: 08 Jan 2021

References

  • Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management and prevention of COPD. Available from: Http://www.goldcopd.com. Accessed December 24, 2020.
  • Miravitlles M, Soler-Cataluña JJ, Calle M, et al. Guía española de la enfermedad pulmonar obstructiva crónica (GesEPOC) 2017. Tratamiento farmacológico en fase estable. Arch Bronconeumol. 2017;53:324–335. doi:10.1016/j.arbres.2017.03.018
  • Wedzicha JA, Miravitlles M, Hurst JR, et al. Management of COPD exacerbations: a European Respiratory Society/American Thoracic Society guideline. Eur Respir J. 2017;49:1600791. doi:10.1183/13993003.00791-2016
  • Miravitlles M, Sliwinski P, Rhee CK, et al. Evaluation of criteria for clinical control in a prospective, international, multicenter study of patients with COPD. Respir Med. 2018;136:8–14. doi:10.1016/j.rmed.2018.01.019
  • Calle Rubio M, Rodríguez Hermosa JL, Soler-Cataluña JJ, et al. Medical care according to risk level and adaptation to Spanish COPD Guidelines (Gesepoc): the Epoconsul Study. Arch Bronconeumol. 2018;54:270–279. doi:10.1016/j.arbres.2017.11.015
  • Hurst JR, Vestbo J, Anzueto A, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med. 2010;363:1128–1138. doi:10.1056/NEJMoa0909883
  • Miravitlles M, Calle M, Soler-Cataluña JJ. Fenotipos clínicos de EPOC: identificación, definición e implicaciones para las guías de tratamiento. Arch Bronconeumol. 2012;48:86–98. doi:10.1016/j.arbres.2011.10.007
  • Esteban C, Castro-Acosta A, Alvarez-Martínez CJ, Capelastegui A, López-Campos JL, Pozo-Rodriguez F. Predictors of one-year mortality after hospitalization for an exacerbation of COPD. BMC Pulm Med. 2018;18:18. doi:10.1186/s12890-018-0574-z.
  • Yang F, Wang Y, Yang C, Hu H, Xiong Z. Mobile health applications in self-management of patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis of their efficacy. BMC Pulm Med. 2018;18:147. doi:10.1186/s12890-018-0671-z
  • Quint JK, Donaldson GC, Hurst JR, Goldring JJP, Seemungal TR, Wedzicha JA. Predictive accuracy of patient-reported exacerbation frequency in COPD. Eur Respir J. 2011;37(3):501–507. doi:10.1183/09031936.00035909
  • Langsetmo L, Platt RW, Ernst P, Bourbeau J. Underreporting exacerbation of chronic obstructive pulmonary disease in a longitudinal cohort. Am J Respir Crit Care Med. 2008;177(4):396–401. doi:10.1164/rccm.200708-1290OC
  • Boer LM, Bischoff EW, Borgijink X, et al. ‘Exacerbation-free time’ to assess the impact of exacerbations in patients with chronic obstructive pulmonary disease (COPD): a prospective observational study. NPJ Prim Care Respir Med. 2018;28(1):12. doi:10.1038/s41533-018-0079-5
  • Wilkinson TM, Donaldson GC, Hurst JR, Seemungal TA, Wedzicha JA. Early therapy improves outcomes of exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2004;169:1298–1303. doi:10.1164/rccm.200310-1443OC
  • Elbert NJ, van Os-medendorp H, van Renselaar W, et al. Effectiveness and cost-effectiveness of ehealth interventions in somatic diseases: a systematic review of systematic reviews and meta-analyses. J Med Internet Res. 2014;16:e110. doi:10.2196/jmir.2790.
  • Ahmed M, Hurst JR. Monitoring of physiological parameters to predict exacerbations of chronic obstructive pulmonary disease (COPD): a systematic review. J Clin Med. 2016;5:108. doi:10.3390/jcm5120108
  • Shaw G, Whelan ME, Armitage LC, et al. Are COPD self-management mobile applications effective? A systematic review and meta-analysis. Primary Care Respiratory Medicine. 2020;30:11. doi:10.1038/s41533-020-0167-1
  • Wedzicha JA, Decramer M, Ficker JH, et al. Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, doubleblind, parallel-group study. Lancet Respir Med. 2013;1:199–209. doi:10.1016/S2213-2600(13)70052-3
  • Wedzicha JA, Banerji D, Chapman KR, et al. FLAME Investigators. Indacaterol-glycopyrronium versus salmeterol-fluticasone for COPD. N Engl J Med. 2016;374:2222–2234. doi:10.1056/NEJMoa1516385
  • Vestbo J, Woodcock A. Clinical trial research in focus: time to reflect on the design of exacerbation trials in COPD. Lancet Respir Med. 2017;5:466–468. doi:10.1016/S2213-2600(17)30177-7
  • Rodriguez Hermosa JL, Fuster Gomila A, Puente Maestu L, et al. Compliance and utility of a smartphone app for the detection of exacerbations in patients with chronic obstructive pulmonary disease: cohort study. JMIR Mhealth Uhealth. 2020;8(3):e15699. doi:10.2196/15699
  • Bhowmik A, Seemungal TA, Sapsford RJ, Wedzicha JA. Relation of sputum inflammatory markers to symptoms and lung function changes in COPD exacerbations. Thorax. 2000;55:114–120. doi:10.1136/thorax.55.2.114
  • Seemungal TA, Donaldson GC, Paul EA, Bestall JC, Jeffries DJ, Wedzicha JA. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1998;157:1418–1422. doi:10.1164/ajrccm.157.5.9709032
  • Donaldson GC, Seemungal TA, Bhowmik A, Wedzicha JA. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax. 2002;57(10):847–852. doi:10.1136/thorax.57.10.847
  • Ferkol T, Schraufnagel D. The global burden of respiratory disease. Ann Am Thorac Soc. 2014;11:404–406. doi:10.1513/AnnalsATS.201311-405PS
  • Rubinsztajn R, Przybyłowski T, Maskey-Warzechowska M, Karwat K, Chazan R. Exacerbations of Chronic Obstructive Pulmonary Disease and quality of life of patients. Adv Exp Med Biol. 2016;884:69–74. doi:10.1007/5584_2015_178
  • Seemungal TA, Wedzicha JA. Exacerbation frequency and FEV1 decline of COPD: is it geographic? Eur Respir J. 2014;43:1220–1222. doi:10.1183/09031936.00046014
  • Harries TH, Thornton H, Crichton S, Schofield P, Gilkes A, White PT. Hospital readmissions for COPD: a retrospective longitudinal study. NPJ Prim Care Respir Med. 2017;27:31. doi:10.1038/s41533-017-0028-8
  • Vogelmeier CF, Criner GJ, Martinez FJ, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 Report: GOLD executive summary. Arch Bronconeumol. 2017;53:128–149. doi:10.1016/j.arbres.2017.02.001
  • European Medicines Agency. Guideline on clinical investigation of medicinal products in the treatment of chronic obstructive pulmonary disease (COPD). 21 June 2012. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-investigation-medicinal-products-treatment-chronic-obstructive-pulmonary-disease_en.pdf. Accessed November 16, 2020.
  • Wedzicha JA, Singh D, Vestbo J, et al. FORWARD Investigators. Extrafine beclomethasone/formoterol in severe COPD patients with history of exacerbations. Respir Med. 2014;108:1153–1162. doi:10.1016/j.rmed.2014.05.013
  • Leidy NK, Wilcox TK, Jones PW, Roberts L, Powers JH, Sethi S, EXACT-PRO Study Group. Standardizing measurement of chronic obstructive pulmonary disease exacerbations: reliability and validity of a patient-reported diary. Am J Respir Crit Care Med. 2011;183:323–329. doi:10.1164/rccm.201005-0762OC.
  • Jones PW, Lamarca R, Chuecos F, et al. Characterisation and impact of reported and unreported exacerbations: results from ATTAIN. Eur Respir J. 2014;44:1156–1165. doi:10.1183/09031936.00038814
  • Agarwal S, LeFevre AE, Lee J, et al. WHO mHealth Technical Evidence Review Group. Guidelines for reporting of health interventions using mobile phones: mobile health (mHealth) evidence reporting and assessment (mERA) checklist. BMJ. 2016;352:i1174. doi:10.1136/bmj.i1174
  • World Health Organisation. MHealth: new horizons for health through mobile technologies. 2011. doi:10.4258/hir.2012.18.3.231
  • Williams V, Price J, Hardinge M, Tarassenko L, Farmer A. Using a mobile health application to support self-management in COPD: a qualitative study. Br J Gen Pract. 2014;64:e392–400. doi:10.3399/bjgp14X680473
  • O´Reilly JF, Williams AE, Holt K, Defining RL. COPD exacerbations: impact on estimation of incidence and burden in primary care. Prim Care Respir J. 2006;15:346–353. doi:10.1016/j.pcrj.2006.08.009
  • Walters EH, Walters J, Wills KE, Robinson A, Wood-Baker R. Clinical diaries in COPD: compliance and utility in predicting acute exacerbations. Int J Chron Obstruct Pulmon Dis. 2012;7:427–435. doi:10.2147/COPD.S32222
  • Johnston NW, Lambert K, Hussack P, et al. Detection of COPD exacerbations and compliance with patient-reported daily symptom diaries using a smart phone-based information system. Chest. 2013;144:507–514. doi:10.1378/chest.12-2308
  • Mackay AJ, Donaldson GC, Patel AR, Singh R, Kowlessar B, Wedzicha JA. Detection and severity grading of COPD exacerbations using the exacerbations of chronic pulmonary disease tool (EXACT). Eur Respir J. 2014;43:735–744. doi:10.1183/09031936.00110913
  • Scioscia G, Blanco I, Arismendi E, et al. Different dyspnoea perception in COPD patients with frequent and infrequent exacerbations. Thorax. 2017;72:117–121. doi:10.1136/thoraxjnl-2016-208332
  • Iyer AS, Bhatt SP, Garner JJ, et al. Depression is associated with readmission for acute exacerbation of chronic obstructive pulmonary disease. Ann Am Thorac Soc. 2016;13(2):197–203. doi:10.1513/AnnalsATS.201507-439OC